Photo - Myelin-H
57769

Myelin-H

Luxembourg
Market: Other
Stage of the project: Operating business

Date of last change: 14.06.2022
Go to the owner's profile
3
equalizer from 2000
help
Calculated and estimated occupancy of the project (more about ratings)
My rating
1
2
3
4
5
6
7
8
9
10
Average rating:
 

Idea

Digitize healthcare: We help doctors monitor, and treat neurological diseases remotely. The right treatement fot the right patient at the right time.

Current Status

Key achievements:
Customers: 3 Hospitals in Europe
3 letters of interest from customers in the US
Funded by the Ministry of the economy in Luxembourg through the fit4start program and private Equity

Problem or Opportunity

There is no available solution to help doctors remotely and quickly monitor disease progression, assess treatment effectiveness, or even perform a customized therapeutic brain stimulation at home to help similar patients.The existing solutions require doctors have to manually inspect collected signals en route to identifying potential biomarkers.
In parallel, clinical trials for new treatments and research in brain diseases is costly and inefficient due to the lack of new technology to accelerate such research.

Solution (product or service)

Myelin-H is a neurotechnology company developing and licensing biologically inspired software technology to help hospitals, doctors, and biopharma companies perform remote monitoring and treatment of neurological diseases remotely.
Using the same technology, we have developed 3 products:
1. For research to help hospitals and biopharma companies with clinical trials and to accelerate drug development.
2. A software device technology for remote monitoring of patients suffering from multiple sclerosis.
3. For space medicine to help astronauts improve their cognitive performances in orbit.

Business model

Myelin-H is a software a Service (SasS) company.
Our model is a yearly subscription to our software with a one time cost for the hardware. We license our software technology to hospitals and biopharma companies (per license per patient per year)

Incubation/Acceleration programs accomplishment

Fit4Start program
5,00
1
2
3
4
5
1 voice
Sign in/Sign up
arrow_back
EN
more_horiz
close
visibility486
star0
Add to favorites
Delete from favorites
share
close
thumb_up0
Like
Unlike
Idea
Current Status
Market
Problem or Opportunity
Solution (product or service)
Competitors
Advantages or differentiators
Finance
Invested in previous rounds, $
Business model
Money will be spent on
Offer for investor
Team or Management
Mentors & Advisors
Lead investor
Risks
Incubation/Acceleration programs accomplishment
Won the competition and other awards
Invention/Patent
Photos
Product Video
Presentation